^
Association details:
| Biomarker: | HER-2 expression |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1
Published date:
12/28/2022
Excerpt:
...we evaluated if pre-established levels of ERBB2 mRNA expression according to the HER2DX standardized assay are associated with response and survival following T-DM1. In ERBB2 low, medium, and high groups, the overall response rate was 0%, 29% and 56%, respectively (P<.001). ERBB2 mRNA was significantly associated with better progression-free survival (p = 0.002) and overall survival (OS; P = 0.02).
DOI:
https://doi.org/10.1093/jnci/djac227
Source:
Title:
237P - HER2DX genomic assay in advanced HER2-positive (HER2+) breast cancer treated with T-DM1
Published date:
09/05/2022
Excerpt:
Here, we evaluated the association of the information provided by the HER2DX assay with T-DM1 benefit and survival....Among all variables, ERBB2 mRNA expression was significantly associated with ORR, PFS and OS….ERBB2 mRNA was also significantly associated with better PFS (Hazard Ratio [HR]=0.73, p=0.032) and better OS (HR=0.69, p=0.038)….HER2DX assay provides prognostic and predictive information following T-DM1 in advanced HER2+ breast cancer.
